RojaRamya Kakarla Sri, Chandrasekhar Rayala, Uloopi K S, Vinay C
Department of Pedodontics and Preventive Dentistry, Vishnu Dental College, Bhimavaram, Andhra Pradesh, India.
Int J Clin Pediatr Dent. 2022;15(Suppl 1):S3-S7. doi: 10.5005/jp-journals-10005-2120.
To evaluate the clinical efficacy of propolis as pulpotomy medicament in human primary molars.
This randomized controlled trial is a two-arm, parallel group study with blinded outcome assessment. The study included a total of 60 primary molars that require pulpotomy treatment in 4 8-year old children. Teeth were assigned to two groups randomly: Propolis (Test group); Mineral trioxide aggregate (MTA) (Control group). All the pulpotomized teeth were given stainless steel crowns and the teeth were evaluated clinically and radiographically at 6, 12, and 24 months to grade them as either success or failure. Chi-square test was employed to analyze the data.
Success rates of pulpotomy with propolis and MTA were 80% and 93.1% respectively at 24 months of follow-up interval. Propolis has shown success rates of 90% and 80% at 6- and 12-month follow-up, while MTA has shown a consistent success rate of 93.1% at all the follow-up intervals. The difference in success rate between the groups at all the time intervals is statistically nonsignificant.
Propolis has demonstrated a clinically acceptable success rate comparable to MTA as pulpotomy medicament in primary teeth.
Biocompatible materials with regenerative potential have drawn the momentum in vital pulp therapy. In this regard, MTA has been emerged as most successful material, but its high cost has limited its use. Hence, there is an absolute need of cost-effective pulpotomy material with regenerative potential. This study provides an evidence that propolis has clinically acceptable success rate as pulpotomy medicament. Considering its low cost and ready availability, it can be recommended as a cost-effective alternative for primary teeth pulpotomy.
RojaRamya KS, Chandrasekhar R, Uloopi KS, Treatment Outcomes of Pulpotomy with Propolis in Comparison with MTA in Human Primary Molars: A 24-month Follow-up Randomized Controlled Trial. Int J Clin Pediatr Dent 2022;15(S-1):S3-S7.
评估蜂胶作为人类乳磨牙牙髓切断术药物的临床疗效。
本随机对照试验为双臂平行组研究,采用盲法评估结果。该研究共纳入4名8岁儿童中60颗需要进行牙髓切断术治疗的乳磨牙。牙齿被随机分为两组:蜂胶组(试验组);三氧化矿物凝聚体(MTA)组(对照组)。所有接受牙髓切断术的牙齿均戴上不锈钢冠,并在6个月、12个月和24个月时进行临床和影像学评估,将其评定为成功或失败。采用卡方检验分析数据。
在24个月的随访期内,蜂胶牙髓切断术和MTA牙髓切断术的成功率分别为80%和93.1%。蜂胶在6个月和12个月随访时的成功率分别为90%和80%,而MTA在所有随访期的成功率均为93.1%。各时间间隔两组成功率的差异无统计学意义。
在乳牙牙髓切断术中,蜂胶作为药物的成功率在临床上是可接受的,与MTA相当。
具有再生潜力的生物相容性材料在活髓治疗中备受关注。在这方面,MTA已成为最成功的材料,但其高成本限制了其应用。因此,迫切需要一种具有再生潜力的经济有效的牙髓切断术材料。本研究提供了证据表明,蜂胶作为牙髓切断术药物具有临床上可接受的成功率。考虑到其低成本和易于获得,可推荐其作为乳牙牙髓切断术的经济有效替代方案。
RojaRamya KS, Chandrasekhar R, Uloopi KS, 与MTA相比,蜂胶用于人类乳磨牙牙髓切断术的治疗结果:一项24个月随访的随机对照试验。《国际临床儿科学牙科杂志》2022;15(S-1):S3-S7。